Optimal Benefits for Hematopoietic Stem Cell Transplantation: A Consensus Opinion  by Maziarz, Richard T. et al.
Biol Blood Marrow Transplant 20 (2014) 1671e1676Biology of Blood and
Marrow Transplantation
journal homepage: www.bbmt.orgOpinionOptimal Beneﬁts for Hematopoietic Stem Cell Transplantation:
A Consensus OpinionRichard T. Maziarz 1,*,y, Stephanie Farnia 2, Patricia Martin 3, Krishna V. Komanduri 4
1Adult Blood and Marrow Transplant Program, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon
2National Marrow Donor Program, Minneapolis, Minnesota
3Anthem Blue Cross and Blue Shield
4Adult Stem Cell Transplant Program, University of Miami Sylvester Cancer Center, Miami, FloridaArticle history:
Received 18 April 2014
Accepted 7 July 2014
Key Words:
Hematopoietic stem cell
transplantation
ConsensusFinancial disclosure: See Acknowle
* Correspondence and reprint re
Cancer Institute, OR Health & Scien
Road, Portland, OR 97239-3098.
E-mail address: maziarzr@ohsu
y On behalf of the Financial W
Donor Program System Capacity In
1083-8791/$ e see front matter 
http://dx.doi.org/10.1016/j.bbmt.20a b s t r a c t
Variability in transplantation beneﬁts may directly affect outcomes of individuals undergoing autologous or
allogeneic hematopoietic stem cell transplantation procedures. The Financial Working Group of the National
Marrow Donor Programesponsored System Capacity Initiative addressed the issue of variable beneﬁts and
reviewed multiple transplantation beneﬁt packages from both public and private payer organizations. On
completion of the review, a consensus was obtained on deﬁning a recipient beneﬁt package that avoids major
coverage gaps that could negatively inﬂuence patient outcomes. The recommendation was to encourage
adoption of these beneﬁts at a national level by payers, beneﬁt brokers/consultants, and sales teams.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Hematopoietic stem cell transplantation (HCT) remains
the standard of care and often the only curative treatment
option for a wide range of diseases, including high-risk and
relapsed hematologic malignancies [1]. Currently, approxi-
mately 20,000 HCT procedures are performed in the United
States each year [2e5]. HCT can be performed with either
autologous (ie, the patient’s own) or allogeneic (from a full or
partially HLA-matched family member or unrelated donor)
hematopoietic stem cells (HSC). The choice of the optimal
HSC source is inﬂuenced by the nature of the underlying
disorder, its responsiveness to chemotherapy, and its sensi-
tivity to the immunologic effects mediated by an allogeneic
donor graft. Medical considerations that may inﬂuence the
decision to proceed to transplantation and the choice of HSC
donor include disease stage and risk of relapse, patient age,
and the presence of medical comorbidities. In addition,
nonmedical reasons, including socioeconomic factors, such
as the availability of a support network and access to ﬁnan-
cial resources, including payer availability, may inﬂuence the
decision to perform HCT.dgments on page 1676.
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14.07.007A recognized but understudied issue has been the impact
of payer source on transplantation outcomes. In the United
States, a multipayer system that includes state and federal
governmental payers, as well as commercial (‘third party’)
sources, exists. As the safety and efﬁcacy of transplantation
have improved over time for most diseases in which autol-
ogous and allogeneic HCT are used, transplantation has
dramatically increased. Given the inevitable increases in
costs associated with providing care for an increased number
of transplantation patients, some payers have placed limi-
tations on transplantation beneﬁts, which may have unin-
tended consequences for key clinical outcomes, including
overall survival and quality of life. Studies have documented
that HCT outcomes can be inﬂuenced by race and ﬁnancial
status, and analyses have suggested that the composition of a
payer beneﬁts package can positively or negatively affect
outcomes [6]. As an example, it has been recognized that
patients who are in need of allogeneic HCToften have beneﬁt
policies with inadequate “donor search” beneﬁtsdmeaning
coverage for the costs of ﬁnding and typing potential allo-
geneic donors. Clinical trial coverage varies by payer andmay
improve somewhat under the new requirements of the
Affordable Care Act (ACA) implemented in 2014, but it is
often a signiﬁcant ﬁnancial barrier, particularly in the case of
emerging disease indications for HCT [7]. Finally, coverage
for obtaining outpatient post-transplantation medications
can be problematic for patients; substantial monthly ex-
penses may be encountered because of high copays and
coinsurance for specialized medications, with vast differ-
ences in coverage observed between individual self-fundedTransplantation.
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payers (eg, Medicare and state Medicaid plans).
THE NATIONAL MARROW DONOR PROGRAM SYSTEM
CAPACITY INITIATIVE FINANCIAL WORKING GROUP
In September 2009, the National Marrow Donor Program
(NMDP) organized the System Capacity Initiative (SCI), a 3-
year project to assess the current health care system’s abil-
ity to accommodate the predicted growth in the number of
patients who will need an HCT by 2020. The SCI initiative
addressed, through the formation of individual working
groups, a wide range of HCT-related issues, including work-
force availability, care delivery systems, education, access,
and reimbursement [8,9]. As part of this initiative, a Financial
WorkingGroup (FWG)was assembled to identify and address
ﬁnancial barriers to transplantation. The FWG members
represented a cross-section of the transplantation commu-
nity, including transplantation medical directors, represen-
tatives of leading commercial payers, including medical and
program directors responsible for payment for complex
medical services, transplantation center administrators, and
transplantation-speciﬁc risk management and contracting
organizations leaders.
The initial efforts of the FWG were focused on identifying
the scope of its activities, and, ultimately, in deﬁning areas
which the multidisciplinary FWG could provide guidance to
the transplantation and payer communities. Under the
auspices of the US Health Resources and Services Adminis-
tration, an initiative to deﬁne a modern list of diseases
appropriately treated with HCT, and for which coverage
should be provided, was already underway and continues at
present; therefore, it was felt that the group should support
and not duplicate its efforts. Endorsement was provided for
the need to create a catalogue of individual state Medicaid
beneﬁts, and this effort was individually pursued by the
health services research division of the NMDP [10]. Ulti-
mately, the entire committee decided to focus on 4 major
issues, with the recognition that the effort could be
completed within the 36-month period and yield working
products that reﬂected a consensus opinion of the members
of the diverse group. These projects included the following:
(1) the creation of consensus guidelines that would deﬁne
the appropriate beneﬁt package for the HCT recipient, (2) the
development of tools to enhance the efﬁciency of the pre-
authorization process for private payers, (3) the creation of
materials and tools to educate transplantation centers on the
complexity of coding in reimbursement, and (4) the gener-
ation of a plan to communicate these consensus opinions and
tools for the broader HCT community, including trans-
plantation medical directors, center administrators, leader-
ship within groups of public and commercial payers, and the
greater health care purchaser industry involved in trans-
plantation beneﬁts formulation and administration, includ-
ing plan managers, beneﬁt consultants, and reinsurers.
METHODS
Process of Beneﬁts Analysis and Development of a Consensus Beneﬁts
Package
An FWG subcommittee was formed to deﬁne the key elements of a
consensus beneﬁt package. The ﬁrst step was the conﬁrmation and ascer-
tainment of the need for a clear set of recipient beneﬁts for patients un-
dergoing allogeneic and autologous HCT, based on available clinical and
administrative best practices. This deliverable was identiﬁed as a priority
effort because of the readily discernible, wide variation in beneﬁts packages
known to the subcommittee members. The group acquired, and reviewed in
detail, information regarding individual beneﬁt packages from a wide range
of commercial payers and the available beneﬁts provided by various stateMedicaid agencies andMedicare coverage standards. There was a consensus
that many governmental payers, particularly state Medicaid plans, provided
limited and often inadequate HCT beneﬁts, an observation that led to an
independent NMDP policy team analysis, which conﬁrmed this view [9]. The
group also recognized that there has been extensive growth in the number
of self-funded plans that, although often administered by major commercial
payers, were the ultimate arbiters of beneﬁts provided to their own em-
ployees. There was also recognition that HCT-associated beneﬁts may not be
entirely deﬁned by the primary payer, but that reinsurer groups can also be
responsible for transplantation and other complex services carved out of the
primary beneﬁts package. Speciﬁcally, there was a focused effort to examine
both beneﬁts provided by entities that provide reinsurance coverage to an
employer’s self-insured beneﬁt plan (the circumstance where the reinsurer
does not deﬁne beneﬁts under the employer’s plan but rather establishes
which beneﬁts are covered under the reinsurance coverage) and a second
group of payer entities that provide insurance (not reinsurance) coverage for
transplantation beneﬁts that have truly been carved out of the medical
beneﬁt set. In this latter circumstance, the entity is providing fully insured
(not self-insured) coverage for a deﬁned set of transplantation services that
has been carved outdie, excludeddunder the employer’s self-insured
beneﬁt plan, thus protecting the employer from the ﬁnancial risk associ-
ated with variability in delivery of transplantation services.
As a next step, the working group documented beneﬁts that were uni-
versally included within multiple plans. The group then generated a process
map required by the transplant recipient, recognizing the high variability of
clinical course, based upon the type of transplantation that was to be un-
dertaken. With these steps completed, the group assessed frequent in-
congruities between beneﬁt plans and also identiﬁed common gaps in
coverage. The potential clinical consequences of coverage gaps were then
discussed and evaluated, with consideration of the costs associated with
coverage and the potential unintended consequences (clinical and ﬁnancial)
of beneﬁt limitations. The ﬁnal steps of the process were to create a docu-
ment deﬁning a recommended set of insurance beneﬁts derived from clear
consensus of all stakeholders and of sufﬁciently high visibility to encourage
near-universal adoption by all payers, beneﬁt brokers/consultants, and ac-
count sales teams.
RESULTS
Recommended Beneﬁts for HCT
Beneﬁts described are those that the committee felt pro-
vided appropriate support to a patient and his/her care team
to maximize the likelihood of achieving optimal HCT out-
comes (Table 1). Coverage for HCT and all subsequent thera-
peutic interventions, and support for travel and lodging, as
well as for outpatient care and caregiver requirements, should
be provided for any patient with a medically necessary indi-
cation and adequate physiologic reserve such that acceptable
long-term outcomes could be achieved. Transplantation in-
dications are expanding rapidly and it is recognized that HCT
maybe either a curative option or life-extendingprocedure for
many patients. Limiting or delaying access to transplantation
may result in increased costs and poor patient outcomes,
including death. Financial limits for reimbursement of HCT
costs, either for the procedure or for medical costs over a pa-
tient’s lifetime, should not have predetermined restrictive
ceilings. Determination of the diagnostic indications for HCT
procedures was not felt to be the purview of the subcom-
mittee, but rather, deferred to national organizations or payer
bodies performing evidence-based assessments of the value
of HCTcomparedwith alternate strategies that are continually
evolving.
Donor Search
In the case of an allogeneic HCT, coverage should be pro-
vided for HLA typing of the patient and potential donors to
identify the best possible “match” or best available cellular
product. Related donors will primarily include fully HLA-
matched siblings but may also be extended to other family
members, while recognizing that less than fully HLA-matched
donors are acceptable in selected situations. Unrelated donor
HCT procedures have been increasing dramatically over the
Table 1
Beneﬁt Design for Hematopoietic Cell Transplantation: Recommendations for Designing an Effective Health Insurance Beneﬁt Set
Beneﬁt Category Recommendations
Allogeneic donor
search process
Recommendation: Full coverage of tissue typing of patient, potential related donors, and unrelated donors through Be The Match or
other approved registry.
Rationale: Seventy percent of patients do not have a fully matched sibling donor. Limiting or excluding search coverage delays
transplantation and can result in unnecessary and costly complications. Information about average costs and processes can be found
at http://payor.bethematchclinical.org.
Administrative guidance: Place search and procurement beneﬁts in separate categories to ensure availability for each stage.
Requiring proof of donor insurance policy denial for typing will unnecessarily delay the process; all policies prohibit coverage of
costs when a member is acting as a donor. The Medicare claims processing manual indicates that donors should never be billed for
transplantation costs.
Cell procurement
or acquisition
Recommendation: Full coverage of cell source acquisition and transport, including travel and lodging of related donor, for harvest
procedure.
Rationale: Obtaining the cell source is a necessary part of the transplantation process. For allogeneic unrelated HCT, cost of
procurement is dependent on donor location and type of cells selected for transplantation.
Administrative guidance: Place search and procurement beneﬁts in separate categories to ensure availability for each stage.
Cell infusion or
transplantation;
hospital length
of stay
Recommendation: Full coverage of HCT and subsequent therapeutic infusions for all medically necessary indications, including full
coverage of all relevant hospital stays.
Rationale: Transplantation indications are expanding rapidly and improving the lives of patients with otherwise fatal conditions.
Limiting access to HCT as a treatment option may result in increased costs and poor patient outcomes, including death.
Administrative guidance: HCT and the associated services ﬁt within the deﬁnition of Essential Health Beneﬁts as deﬁned by the
Department of Health and Human Services and, therefore, should not be subject to an annual dollar limitation. For information on
transplantation indications, please visit www.CIBMTR.org. Limitation of bed days or hospital days on an annual basis is
counterproductive to treatment and may be life-threatening. Several inpatient visits are needed for treatment of primary disease,
preparation for transplant and recovery. Length of stay varies by disease, condition, cell or graft source success and complications.
Utilization of a standard transplantation authorization form can streamline requests and reduce processing time. A standard form
can be found at www.payor.bethematchclinical.org
Travel and lodging Recommendation: Full coverage of travel and lodging costs for member and caregiver(s) for the transplantation visit, in addition to
necessary pre- and post-transplantation evaluations. Cover costs for additional caregiver travel, if patient is under 18 years of age.
Rationale: Patient will likely have to travel to a transplantation center able to treat their condition and/or within their insurance
network. Allogeneic HCT programs may require patient to stay near center for up to 100 days after transplantation. Limiting travel/
lodging beneﬁts may result in complications caused by delayed care and/or patient seeking care from nonspecialist care teams.
Administrative guidance: Encourage member to use discounted housing options if available through the transplantation program.
Adopt IRS reimbursement guidelines for taxable amounts allowed for health-related travel or allow ﬂexible spending of
plan-determined patient allocation. Patient will need to report to IRS on 1099 form. Consider use of reusable debit card.
Medications Recommendation: Full coverage, without copay or coinsurance, of all necessary medications throughout the HCT process, including
the post-transplantation period.
Rationale: Access to medication is critical for success of HCT. Prohibitive copayments or coinsurance may result in noncompliance,
poor outcomes, graft failure, and/or expensive hospitals readmissions due to infection or complications.
Administrative guidance: Off-label use of medications is common for the treatment of cancer care of all types, including hematologic
malignancies and HCT. Have health plan case management team review list of prescribed medications and work with the patients
pharmacy beneﬁt manager to issue a test claim before discharge.
Clinical trials Recommendation: Full coverage of routine care in clinical trials appropriate to the patient’s disease, treatment stage, and clinical
condition.
Rationale: Limiting access to clinical trials slows improvements in standards of care. Paying for identical care outside of a clinical trial
has identical cost without potential of future beneﬁt.
Administrative guidance: As of 2014, the ACA requires coverage of all routine costs associated with clinical trials that meet
sponsorship or approval requirements.
IRS indicates Internal Revenue Service.
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unrelated adult donors and/or cord blood units should be
covered when facilitated through Be The Match or another
payer-approved donor registry, such as the Anthony Nolan
Registry or the Delete Blood Cancer Deutsche Knochenmark-
spenderdatei gGmbH (Translation: German Bone Marrow
Donor Center). Potential unrelated donors have preliminary
typing results available through the Be The Match registry
but need additional and more detailed conﬁrmatory testing
before selection of the best donor. Limiting or excluding
coverage for donor typing can result in a suboptimal donor
choice, which may lead to increased rates of complications
associated with increased morbidity and mortality, including
graft-versus-host disease and graft rejection. As donation
timelines may vary between individual donors, limitation of
search services may negatively affect transplantation timing,
possibly increasing the risk of disease progression before HCT
or treatment failure after transplantation. Increases in
complication rates and the corresponding consequences of
these complications may increase overall costs. Coverage
should be provided for the medical evaluation of the donor aswell as the requisite laboratory screening needed to identify
potential transmissible hematologic, autoimmune, or infec-
tious diseases. Administrative recommendations for payer
consideration were to place search and procurement funding
into a separate beneﬁts compartment to ensure funds would
be available.
Cell Acquisition and Procurement
Coverage recommendations for cell acquisition vary by
transplant and donor type. Autologous HCT patients need full
coverage for preparation/mobilization, collection, cryopreser-
vation, and storage of cells. Clariﬁcation of the onset of autol-
ogous product mobilization and collection is needed,
recognizing the different approaches (and associated costs)
resulting from strategies that commonly include mobilization
after the administration of cytotoxic chemotherapy followed
by growth factors, compared with the use of growth factors
alone for mobilization of peripheral blood stem cells. Alloge-
neic HCT recipients need full coverage for donor clearance,
preparation, mobilization, and cell collection, transportation,
and delivery costs. This includes costs associated with
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umbilical cord blood products, bone marrow products col-
lected by operative harvesting, or peripheral blood stem cells
products collected by apheresis after administration of growth
factors to healthy donors. In some circumstances, there may
need to be allowances for variable practice, including need for
cryopreservation, thawing, and preparation of HSC, including
enrichment and/or depletion of graft subsets, depending on
the situation and donor source. When a fully or partially HLA-
matched related donor is utilized, coverage for donor travel to
and lodging at the patient’s transplantation center should be
provided, when necessary, in addition to the actual procure-
ment. Administrative recommendations for payer consider-
ation were to place search and procurement funding into a
separate beneﬁts compartment to ensure funds would be
available.
Cell Infusion (“Transplantation”) Procedures
Full coverage of the actual cell infusionprocedure shouldbe
provided. Financial support for management of the primary
hospitalization and long-term medical complications should
be planned. Administrative guidance recommendations
include placing all transplantation beneﬁts under general
medical beneﬁts spending and/or not to implement a separate
transplantation-only beneﬁt and spending limit. This recom-
mendation has been further clariﬁed by the ACA, as trans-
plantation procedures are within the scope of the Essential
Health Beneﬁt set and cannot be restricted by qualiﬁed health
plans. There has been the steady adoption of transplantation
beneﬁts to cover a variably deﬁned episode of care (ie, prepa-
ration, infusion, and a number of recovery days, usually 100),
rather than what is the tightly temporally deﬁned procedure.
There is an emerging understanding that the primary trans-
plantation HSC infusion is distinct from subsequent infusion
episodes (eg, performed to treat graft failure and/or relapse)
and that consistent terminology regardingassociatedpractices
is needed. Recent efforts by professional societies and payers
have led to the development of consensus statements [11], and
the FWG expressed support for further efforts to develop and
maintain consistency of terminology used by various stake-
holders in the HCT community.
Travel and Lodging
Full coverage is recommended for travel and lodging costs
for a patient and his/her caregiver(s) for transplantation can-
didacy evaluation, preparation, and the procedure itself, in
addition to post-transplantation follow-up visits. In the case of
a pediatric or adolescent/young adult patient, coverage for a
second caregiver and/or allowance for alternating caregivers is
often needed and should be covered. Patientsmay be required
to stay within close range of a transplantation center for
several months after HCT, with longer intervals (up to several
months) typically required in the setting of allogeneic trans-
plantation. Limiting travel and lodging beneﬁts may create
ﬁnancial barriers for patients pursuing transplantation as a
treatment option and reduces their ability to seek appropriate
follow-up care with their primary transplantation team,
which may lead to suboptimal management of complications
and increased risk and cost of complications. Payers can
promote the use of discounted housing options offered by
transplantation centers, particularly when relocating patients
to an identiﬁed centerof excellencewithin the transplantation
network. Payers may choose to either adopt Internal Revenue
Service guidelines for these beneﬁts or allowﬂexible spending
of an allowed amount and later issuing an Internal RevenueService form 1099 to the patient. Consideration has been
recommended for providing reloadable debit cards and for
extension of travel and lodging beneﬁts to support daily ex-
penditures, such as food and local travel.
Hospital Care/Length of Stay
There should not be a limit placed on the number of
inpatient days covered for an HCT patient during the course
of a calendar year or subsequent years, as arbitrary limits
could result in suboptimal management of early or late
transplantation complications. The hospital stay for the HCT
conditioning, infusion, and recovery periods can vary based
on a variety of factors that govern transplantation risk (eg,
patient clinical status, disease, graft type) and also the vari-
able incidence of complications even within deﬁned risk
groups. Patients may also face inpatient stays for control of
their malignancy before the transplantation process and
multiple readmissions after transplantation for treatment of
complications. The practice of setting arbitrary limits on
hospital days was considered counterproductive to optimal
treatment and may increase the risk of adverse outcomes
with ultimately increased cost.
Clinical Trials
Coverage of clinical trial participation should be provided
for trials appropriate to the patient’s disease, stage, and clin-
ical condition. Routine costs associatedwith clinical trials that
are federally approved or sponsored (eg, HCT trials supported
by the National Heart Lung Blood Institute (NHLBI) and Na-
tional Cancer Institutes (NCI), including multicenter or single
center studies performed at NCI-designated cancer centers)
are required of most health insurance policies as of January 1,
2014, under the provisions of the ACA. However, coverage for
well-designed clinical trials that have not secured federal
funding should also be considered when recommended by a
patient’s care team, particularly for emerging transplantation
indications. Well-designed, statistically sound, single insti-
tution, scientiﬁcally innovative trials, such as the recently
published studies of chimeric antigen receptor-T cells in
relapsed acute lymphoid leukemia from the University of
Pennsylvania Abramson Cancer Center have played an im-
portant role in furthering the HCT ﬁeld [12]. Limiting patient
access only to multicenter, well-designed, nationally sup-
ported clinical trials has the risk of slowing improvement in
standards of care that otherwisewould continue to evolve at a
high rate, given the rapid pace of scientiﬁc and clinical de-
velopments relevant to HCT. Paying for identical care outside
of a clinical trial has identical cost without the collective
societal beneﬁt gained via clinical trials. HCT is an area of
medicinewithahighproportionof patients treatedonclinical
trials because of the complexity of the treatment, the variety
of diseases treated, and the rapid evolution of best practices,
including those efforts spearheaded by research consortiums
that include the NHLBI- and NCI-sponsored Blood and
Marrow Transplant Clinical Trials Network [13,14].
Prescription Medication
The HCT process is dependent onprescriptionmedications,
often required for years, that include antimicrobials agents, for
prophylaxis and therapy, and immunosuppressive medica-
tions critical to the safety and success of allogeneic trans-
plantation. Coverage of all necessary medications, particularly
post-transplantation medications, should be provided, ideally
with waived coinsurance or copay responsibilities. There was
strongconsensus thatcost-sharingprovisions intended to limit
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setting, to result in noncompliance, leading to signiﬁcant
complications, including higher rates of graft-versus-host
disease and/or infections, both of which are important causes
of morbidity and mortality after HCT. Thus, noncompliance
related to the ﬁnancial burden of coinsurance or copay costs
may result in poor outcomes and, ultimately, in expensive
hospital readmissions. Off-label use of medications is com-
monplace in cancer treatment protocols and in supportive care
of HCT patients, supported by a strong evidence base for mul-
tiple off-label medications used in HCT patients. A review of
patients’ medications between all stakeholders is recom-
mended before discharge, as is a test claim of the medications
to identify cost and/or coverage problems. A test claim is the
“dummy” submission of the prescription claim from the
hospital to the payer, which results in detailed information
as to any potential copays, formulary issues, and denied
medications.
DISCUSSION
The management of the HCT recipient, whether the pa-
tient has undergone an autologous or allogeneic procedure,
is a complex process requiring extensive medical evaluation,
the complex delivery of ambulatory and inpatient services,
and a need for ongoing diagnostic clinical and laboratory
evaluations. All of these efforts must be performed with
ongoing awareness and attention to the underlying disease
and associated medical comorbidities, with contextual clin-
ical decision-making considering a variety of socioeconomic
factors, such as patient education, caregiver support, and
access to health care systems; all of these factors ultimately
inﬂuence individual patient outcomes. Not surprisingly, the
total costs of HCT will be signiﬁcant andmay be accrued over
an extended period of time [15,16]. Total HCT episode costs
are likely to continue to rise because of expanded utilization
of HCT and improved survival after transplantation. The
increasing costs of HCT must be considered in the context of
rising general costs for the diseases most often indicated for
transplantation, as leukemia and lymphoma have already
been identiﬁed by the NCI within the top 6 cancer disease
categories that result in the greatest annual cancer expen-
diture [17]. To maximize the possibility of achieving optimal
outcomes, the workforce must be intact [18] and the ﬁnan-
cial support and clinical infrastructure needed to provide
care to individuals undergoing intensive cancer therapies
must be assured. These goals motivated the establishment of
the NMDP SCI and its subcommittees, including the FWG,
which identiﬁed a high-priority need to deﬁne the key
elements of an effective ﬁnancial beneﬁts package for the
transplantation patient and to subsequently facilitate un-
derstanding and adoption of these recommendations.
This manuscript has described the details of the recom-
mended transplantation recipient beneﬁt package, outlining
the importance of subcategories that need to be considered.
Historically, there has been a tendency to fragment trans-
plantation beneﬁts packages, with independent allocations
for individual elements of care (eg, search, transplantation
medical beneﬁts, and general medical care). This compart-
mentalization may contribute to disjointed and often sub-
optimal care of the HCT patient. Dramatic variations in payer
beneﬁts packages may also limit the ability of trans-
plantation centers to practice consistent and evidenced-
based care or develop clear patient medical pathways,
resulting in a need to deviate from uniform care standards as
a result of restraints imposed by divergent beneﬁts packages.The effort of the FWG to deﬁne a transplant recipient beneﬁt
package is an important ﬁrst step toward improving the
consistency of care and an iterative process, wherein out-
comes are optimized while minimizing the costs of care to
the individual patient and to the health care system. We
recognize that adopting any perceived expansion of beneﬁts
requires a detailed cost analysis of the total episode of care to
determine if additional costs to the system have been
incurred but ideally, an optimal beneﬁt package could
contribute to outcome improvement in diminished compli-
cations through additional supportive care. We also recog-
nize that there already exists signiﬁcant variation in
inpatient costs among HCT transplantation centers, as
recently documented by the analysis of Thao et al. [19]. We
also anticipate that there will be ongoing analysis during the
expected evolution of care delivery as a product of expansion
of the transplantation-eligible patient population that will be
the result of the ACA; the 2014 implementation of key pro-
visions of the ACA impact access to HCT in numerous ways
and a separate and speciﬁc analysis has recently been pub-
lished by the NMDP health policy team [20].
We expect these guidelines to be reviewed by trans-
plantation centers and payers, yielding further discussion
and action, and immediate consequences of this consensus
effort are already evident. Using the recipient beneﬁt pack-
age as a model for care, a review of Oregon Health and Sci-
ence University’s institutional requests for transplantation
beneﬁts was performed and in a 4-month time line, 50%
of the requests for preauthorization failed to meet SCI
beneﬁt guidelines (Maziarz, unpublished data: Oral pre-
sentationdNMDP Blood and Marrow Transplant: A Forum
on Quality, Transparency, Cost, and Value [July 2013]). Pre-
ussler et al. have reviewed the US Medicaid programs and
have demonstrated that no state provides coverage in all
beneﬁt categories [10]. Three states had adequate beneﬁts
for 4 of the categories; 21 states had adequate coverage for 3
categories; 15 states had adequate coverage for only 2 of the
categories, and 8 states, including 2 of the most populous
states of the country, met the proposed beneﬁts in only 1
transplantation beneﬁt category. These data suggest that
education and advocacy will be necessary to ensure
improvement of beneﬁts packages at the state level.
On a more positive note, as a result of the generation of
the SCI recommendation for covered transplantation bene-
ﬁts, the National Comprehensive Cancer Network and the
National Business Group on Health have integrated these
beneﬁt recommendations into their Employer’s Guide to
Cancer Treatment and Prevention [21]. The National Business
Group on Health/National Comprehensive Cancer Network
series provides reference tools speciﬁc to cancer care and
treatment for employers who are purchasing health care
beneﬁts. They recommend that coverage include pre-
transplantation, transplantation, and post-transplantation
care recommended by the transplantation center and that
the beneﬁt plan also include donor search and typing costs
including: “full cost of biological sibling typing; full cost of
unrelated donor search, including typing and testing of po-
tential donors, through the NMDP or other approved regis-
try; full cost of related donor procurement, including travel
and lodging of the selected related donor for the donation
process; and full cost of donor cell product procurement for
the unrelated donor” [21]. Ongoing outreach activities are
planned, through the NMDP and afﬁliated organizations, to
extend education about and adoption of these consensus
recommendations.
R.T. Maziarz et al. / Biol Blood Marrow Transplant 20 (2014) 1671e16761676CONCLUSION
HCT is an important but complex treatment modality and
continues to be utilized in an expanding fashion because of
improved safety and efﬁcacy for a broad range of indications.
Although expensive, HCT has also been demonstrated to be
cost effective for many indications, and it is often the treat-
ment modality most likely to be curative or extend life in
transplantation candidates. For underinsured or uninsured
transplantation patients, facing the complex process of care
with limited or no health insurance beneﬁts is daunting and
is very likely to undermine the likelihood of success. Because
the major component of payer cost is for the transplantation
procedure and hospitalization, attempts to control costs for
ancillary processes or procedures, supportive care of the
patient, or medications may paradoxically increase care
because of an unintended increased risk of complications. It
is the hope of the working group that all patients undergoing
HCT will be able to concentrate on their compliance, recov-
ery, healing, and quality of life rather than the long-term
ﬁnancial implications of their treatment.
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